Robotic versus Open Surgery in Locally Advanced Non-Small Cell Lung Cancer: Evaluation of Surgical and Oncological Outcomes
Locally advanced non-small cell lung cancer (NSCLC) consists of a heterogeneous group, with different pulmonary extension and lymph nodal involvement. Robotic surgery can play a key role in these tumours thanks to its technological features, although open surgery is still considered the gold-standar...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-10-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/30/10/658 |
| _version_ | 1797574177839906816 |
|---|---|
| author | Carmelina C. Zirafa Gaetano Romano Elisa Sicolo Elena Bagalà Beatrice Manfredini Greta Alì Andrea Castaldi Riccardo Morganti Federico Davini Gabriella Fontanini Franca Melfi |
| author_facet | Carmelina C. Zirafa Gaetano Romano Elisa Sicolo Elena Bagalà Beatrice Manfredini Greta Alì Andrea Castaldi Riccardo Morganti Federico Davini Gabriella Fontanini Franca Melfi |
| author_sort | Carmelina C. Zirafa |
| collection | DOAJ |
| description | Locally advanced non-small cell lung cancer (NSCLC) consists of a heterogeneous group, with different pulmonary extension and lymph nodal involvement. Robotic surgery can play a key role in these tumours thanks to its technological features, although open surgery is still considered the gold-standard approach. Our study aims to evaluate the surgical and oncological outcomes of locally advanced NSCLC patients who underwent robotic surgery in a high-volume centre. Data from consecutive patients with locally advanced NSCLC who underwent robotic lobectomy were retrospectively analysed and compared with patients treated with open surgery. Clinical characteristics and surgical and oncological information were evaluated. From 2010 to 2020, 131 patients underwent anatomical lung resection for locally advanced NSCLC. A total of 61 patients were treated with robotic surgery (46.6%); the median hospitalization time was 5.9 days (range 2–27) and the postoperative complication rate was 18%. Open surgery was performed in 70 patients (53.4%); the median length of stay was 9 days (range 4–48) and the postoperative complication rate was 22.9%. The median follow-up time was 70 months. The 5-year overall survival was 34% in the robotic group and 31% in the thoracotomy group. Robotic surgery can be considered safe and feasible not only for early stages but also for the treatment of locally advanced NSCLC. |
| first_indexed | 2024-03-10T21:20:11Z |
| format | Article |
| id | doaj.art-f550194275b841b89c44eb1c1e97d4df |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-10T21:20:11Z |
| publishDate | 2023-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-f550194275b841b89c44eb1c1e97d4df2023-11-19T16:11:02ZengMDPI AGCurrent Oncology1198-00521718-77292023-10-0130109104911510.3390/curroncol30100658Robotic versus Open Surgery in Locally Advanced Non-Small Cell Lung Cancer: Evaluation of Surgical and Oncological OutcomesCarmelina C. Zirafa0Gaetano Romano1Elisa Sicolo2Elena Bagalà3Beatrice Manfredini4Greta Alì5Andrea Castaldi6Riccardo Morganti7Federico Davini8Gabriella Fontanini9Franca Melfi10Minimally Invasive and Robotic Thoracic Surgery, Surgical, Medical, Molecular, and Critical Care Pathology Department, University Hospital of Pisa, 56124 Pisa, ItalyMinimally Invasive and Robotic Thoracic Surgery, Surgical, Medical, Molecular, and Critical Care Pathology Department, University Hospital of Pisa, 56124 Pisa, ItalyMinimally Invasive and Robotic Thoracic Surgery, Surgical, Medical, Molecular, and Critical Care Pathology Department, University Hospital of Pisa, 56124 Pisa, ItalyMinimally Invasive and Robotic Thoracic Surgery, Surgical, Medical, Molecular, and Critical Care Pathology Department, University Hospital of Pisa, 56124 Pisa, ItalyDivision of Thoracic Surgery, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, 41121 Modena, ItalyPathological Anatomy, Surgical, Medical, Molecular, and Critical Care Pathology Department, University Hospital of Pisa, 56124 Pisa, ItalyMinimally Invasive and Robotic Thoracic Surgery, Surgical, Medical, Molecular, and Critical Care Pathology Department, University Hospital of Pisa, 56124 Pisa, ItalySection of Statistics, University Hospital of Pisa, 56124 Pisa, ItalyMinimally Invasive and Robotic Thoracic Surgery, Surgical, Medical, Molecular, and Critical Care Pathology Department, University Hospital of Pisa, 56124 Pisa, ItalyPathological Anatomy, Surgical, Medical, Molecular, and Critical Care Pathology Department, University Hospital of Pisa, 56124 Pisa, ItalyMinimally Invasive and Robotic Thoracic Surgery, Surgical, Medical, Molecular, and Critical Care Pathology Department, University Hospital of Pisa, 56124 Pisa, ItalyLocally advanced non-small cell lung cancer (NSCLC) consists of a heterogeneous group, with different pulmonary extension and lymph nodal involvement. Robotic surgery can play a key role in these tumours thanks to its technological features, although open surgery is still considered the gold-standard approach. Our study aims to evaluate the surgical and oncological outcomes of locally advanced NSCLC patients who underwent robotic surgery in a high-volume centre. Data from consecutive patients with locally advanced NSCLC who underwent robotic lobectomy were retrospectively analysed and compared with patients treated with open surgery. Clinical characteristics and surgical and oncological information were evaluated. From 2010 to 2020, 131 patients underwent anatomical lung resection for locally advanced NSCLC. A total of 61 patients were treated with robotic surgery (46.6%); the median hospitalization time was 5.9 days (range 2–27) and the postoperative complication rate was 18%. Open surgery was performed in 70 patients (53.4%); the median length of stay was 9 days (range 4–48) and the postoperative complication rate was 22.9%. The median follow-up time was 70 months. The 5-year overall survival was 34% in the robotic group and 31% in the thoracotomy group. Robotic surgery can be considered safe and feasible not only for early stages but also for the treatment of locally advanced NSCLC.https://www.mdpi.com/1718-7729/30/10/658locally advanced non-small cell lung cancerNSCLCrobotic surgeryminimally invasive surgery (MIS)surgical resultsoncological outcomes |
| spellingShingle | Carmelina C. Zirafa Gaetano Romano Elisa Sicolo Elena Bagalà Beatrice Manfredini Greta Alì Andrea Castaldi Riccardo Morganti Federico Davini Gabriella Fontanini Franca Melfi Robotic versus Open Surgery in Locally Advanced Non-Small Cell Lung Cancer: Evaluation of Surgical and Oncological Outcomes Current Oncology locally advanced non-small cell lung cancer NSCLC robotic surgery minimally invasive surgery (MIS) surgical results oncological outcomes |
| title | Robotic versus Open Surgery in Locally Advanced Non-Small Cell Lung Cancer: Evaluation of Surgical and Oncological Outcomes |
| title_full | Robotic versus Open Surgery in Locally Advanced Non-Small Cell Lung Cancer: Evaluation of Surgical and Oncological Outcomes |
| title_fullStr | Robotic versus Open Surgery in Locally Advanced Non-Small Cell Lung Cancer: Evaluation of Surgical and Oncological Outcomes |
| title_full_unstemmed | Robotic versus Open Surgery in Locally Advanced Non-Small Cell Lung Cancer: Evaluation of Surgical and Oncological Outcomes |
| title_short | Robotic versus Open Surgery in Locally Advanced Non-Small Cell Lung Cancer: Evaluation of Surgical and Oncological Outcomes |
| title_sort | robotic versus open surgery in locally advanced non small cell lung cancer evaluation of surgical and oncological outcomes |
| topic | locally advanced non-small cell lung cancer NSCLC robotic surgery minimally invasive surgery (MIS) surgical results oncological outcomes |
| url | https://www.mdpi.com/1718-7729/30/10/658 |
| work_keys_str_mv | AT carmelinaczirafa roboticversusopensurgeryinlocallyadvancednonsmallcelllungcancerevaluationofsurgicalandoncologicaloutcomes AT gaetanoromano roboticversusopensurgeryinlocallyadvancednonsmallcelllungcancerevaluationofsurgicalandoncologicaloutcomes AT elisasicolo roboticversusopensurgeryinlocallyadvancednonsmallcelllungcancerevaluationofsurgicalandoncologicaloutcomes AT elenabagala roboticversusopensurgeryinlocallyadvancednonsmallcelllungcancerevaluationofsurgicalandoncologicaloutcomes AT beatricemanfredini roboticversusopensurgeryinlocallyadvancednonsmallcelllungcancerevaluationofsurgicalandoncologicaloutcomes AT gretaali roboticversusopensurgeryinlocallyadvancednonsmallcelllungcancerevaluationofsurgicalandoncologicaloutcomes AT andreacastaldi roboticversusopensurgeryinlocallyadvancednonsmallcelllungcancerevaluationofsurgicalandoncologicaloutcomes AT riccardomorganti roboticversusopensurgeryinlocallyadvancednonsmallcelllungcancerevaluationofsurgicalandoncologicaloutcomes AT federicodavini roboticversusopensurgeryinlocallyadvancednonsmallcelllungcancerevaluationofsurgicalandoncologicaloutcomes AT gabriellafontanini roboticversusopensurgeryinlocallyadvancednonsmallcelllungcancerevaluationofsurgicalandoncologicaloutcomes AT francamelfi roboticversusopensurgeryinlocallyadvancednonsmallcelllungcancerevaluationofsurgicalandoncologicaloutcomes |